Welcome to our dedicated page for Collplant Biotechnologies SEC filings (Ticker: CLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CollPlant Biotechnologies Ltd (NASDAQ: CLGN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. CollPlant files annual reports on Form 20-F and current reports on Form 6-K under the Securities Exchange Act of 1934. These documents include press releases on financial results, product development updates, distribution agreements, corporate governance matters and interim financial statements.
Through its Form 6-K submissions, CollPlant furnishes materials such as quarterly financial results, condensed consolidated interim financial statements, operating and financial reviews, and detailed press releases on topics like expansion of rhCollagen distribution capabilities in North America, positive non-clinical data for its photocurable dermal and soft tissue filler, and distribution expansion for its Vergenix STR tendon-repair product in Europe. Filings also cover announcements related to scientific collaborations, including studies involving its Collink.3D rhCollagen-based bioink and Mayo Clinic’s fully humanized 3D bioprinted skin model, as well as notices of shareholder meetings and proxy materials.
On Stock Titan, these SEC filings are paired with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand financial performance, progress in regenerative and aesthetic medicine programs, and material agreements such as CollPlant’s development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company. Real-time updates from EDGAR ensure that new 6-K and 20-F reports are available promptly.
Users can review CollPlant’s historical and current filings to analyze trends in its rhCollagen-based business, monitor disclosures about collaborations and product pipelines, and better understand the regulatory context of its 3D bioprinting, tissue repair and medical aesthetics activities.
CollPlant Biotechnologies Ltd. reported that it will hold an annual and extraordinary general meeting of shareholders on December 31, 2025, at 10:00 a.m. Israel time. The meeting will take place at the offices of Goldfarb Gross Seligman & Co. in the Azrieli Center in Tel-Aviv, Israel.
To support this meeting, CollPlant is providing a notice and proxy statement and a proxy card for holders of ordinary shares. The report is also incorporated by reference into several of the company’s existing Form S-8 and Form F-3 registration statements, meaning those registration statements will now include this information as part of their disclosure record.
CollPlant Biotechnologies filed a Form 6-K reporting it issued a press release titled “CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada.” The release is furnished as an exhibit to the report. The update highlights broader distribution coverage for the company’s rhCollagen across the U.S. and Canada.
CollPlant Biotechnologies (CLGN) filed a Form 6-K noting it issued a press release on October 16, 2025 titled “First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk.” The notice highlights Mayo Clinic researchers’ work and references CollPlant’s rhCollagen-based BioInk. No additional operational or financial details are included in this filing excerpt.
CollPlant Biotechnologies Ltd (CLGN) filed a Form 144 notifying a proposed sale of 140,000 ordinary shares through UBS Securities LLC with an aggregate market value of
The shares were acquired in a private placement from the issuer on
CollPlant Biotechnologies Ltd (CLGN) Schedule 13D shows members of the Loewenbaum family and related trusts collectively beneficially own 1,698,533 ordinary shares, representing 13.4% of outstanding shares based on 12,716,014 shares outstanding as of June 30, 2025. Individual holdings disclosed include George W. Loewenbaum with 1,256,056 shares (9.9%), Lillian S. Loewenbaum with 186,289 shares (1.5%), and several trusts and entities holding the remainder. Recent open-market purchases in late July 2025 at prices from $2.25 to $2.41 are reported. The stated purpose is investment; no present plans to effect corporate changes, but the group will continue to review its position. A Joint Filing Agreement governs the filing.
FAQ
What is the current stock price of Collplant Biotechnologies (CLGN)?
What is the market cap of Collplant Biotechnologies (CLGN)?
